IHC of CK17 on an FFPE Cervical Carcinoma Tissue

IHC of CK 17 on an FFPE Cervical Cancer Tissue

Specification Sheets
Safety Data Sheet

SDS

Intended Use For In Vitro Diagnostic Use
Summary and Explanation Cytokeratin 17 (CK 17) is a Type I cytokeratin with a MW of 46 kD found sometimes in association with Cytokeratin 7. Cytokeratin 17 is found in nail beds, hair follicles, sebaceous glands, and other epidermal appendages. Mutations in the gene encoding this protein lead to Jackson-Lawler type Pachyonychia Congenita and Steatocystoma Multiplex.Cytokeratin 17 antibody has been used to distinguish immature Cervical Squamous Metaplasia from High Grade Cervical Intraepithelial Neoplasia (CIN III). Anti-CK 17 also labels myoepithelial cells in the benign breast tissue. CK 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK 5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact
with basal cytokeratins including anti-CK 17. The histologic differentiation of
ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK 17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.
Antibody Type Mouse Monoclonal Clone BSB-33
Isotype IgG2a/K Reactivity Paraffin, Frozen
Localization Cytoplasmic Control Skin, Testis, Breast, Cervix, Cervical Carcinoma, Bladder TCC
Presentation Cytokeratin 17 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
Availability
Catalog No. Antibody Type Dilution Volume/QTY
BSB 2726 Prediluted Ready-To-Use 3.0 ml
BSB 2727 Prediluted Ready-To-Use 7.0 ml
BSB 2728 Prediluted Ready-To-Use 15.0 ml
BSB 2729 Concentrated 1:25-1:100 0.1 ml
BSB 2730 Concentrated 1:25-1:100 0.5 ml
BSB 2731 Concentrated 1:25-1:100 1.0 ml
BSB 2732 Control Slides 5
Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.
Related Products